BOULDER, Colo., January 15, 2020 — SomaLogic announced today that it has launched three additional SomaSignal™ tests to further empower individuals to manage their state of health more effectively. These new blood-based tests measure:
- Glucose Tolerance — i.e., how well the body processes sugar
- Visceral Fat — i.e., how much fat surrounds the body organs
- Resting Energy Rate — i.e., how many calories the body burns at rest
These three new tests will be added to the seven original SomaSignal™ tests launched last September, which measure primary cardiovascular risk, secondary cardiovascular risk, alcohol impact, liver fat, body fat percentage, lean body mass and cardiorespiratory fitness.
SomaSignal™ tests derive meaningful health information from measuring thousands of different proteins in a small blood sample and then using advanced computer techniques to look for protein patterns associated with disease. Test results are derived from the same blood sample and are delivered simultaneously to provide a holistic view of a person’s current cardiometabolic health and health trajectory.
The ten current SomaSignal™ tests are offered today through 13 healthcare providers in 9 Colorado-based practices at the introductory price of US$199. New providers, locations and tests for additional diseases and conditions continue to be added on a regular basis. For more information and to stay up to date, please visit www.somalogic.com/somasignals.
All SomaSignal™ tests are developed and their performance characteristics determined by SomaLogic, Inc. They have not been cleared or approved by the US Food and Drug Administration.